LSD: all studies (page 3) - The Consciousness Library

The impact of fluoxetine on the aversive effects of lysergic acid diethylamide.

Experimental and Clinical Psychopharmacology August 10, 2026

The impact of fluoxetine on the aversive effects of lysergic acid diethylamide.

The toxicity of psychedelic LSD derivatives: 1-acetyl-LSD (ALD-52), 1-propionyl-LSD (1P-LSD), 1-butyryl-LSD (1B-LSD), 1-valeryl-LSD (1V-LSD) and 1-cyclopropylmethanoyl-LSD (1cP-LSD)-prediction of toxicological parameters relevant to clinical and forensic toxicology using multi-in silico approach.

Archives of Toxicology July 1, 2026 Kamil Jurowski, Alicja Krośniak, Damian Kobylarz et al.

Lysergamide analogs such as ALD-52, 1P-LSD, 1B-LSD, 1 V-LSD, and 1cP-LSD have emerged as new psychoactive substances (NPS) with hallucinogenic potential, yet their toxicological profiles remain largely unexplored. In this study, a comprehensive in silico assessment was conducted using multiple platforms (e.g., ADMETlab 3.0, Percepta, STopTox, ProTox 3.0, VEGA, TEST 5.1.2) to predict critical...

DOI: 10.1007/s00204-025-04255-1 Full text Forensic toxicology Lysergamide analogs New psychoactive substance Toxicology in silico

Effects of repeated low-dose LSD on neuropsychological functioning in adults with ADHD: a randomized placebo-controlled study

Psychopharmacology June 20, 2026 E. C. H. M. Haijen-Bongers, Petra P M Hurks, J. Schepers et al.

RATIONALE: Attention-deficit hyperactivity disorder (ADHD) shows substantial heterogeneity in symptoms and cognitive deficits. According to the Triple Pathway Model, this variability may stem from impairments in three neuropsychological domains: inhibition, motivation, and temporal processing. Repeated low-dose administration of psychedelics is being explored as a treatment for ADHD, but...

DOI: 10.1007/s00213-026-07107-7 Full text Neuropsychology Placebo Cognition Population +8

Acute and post-acute neurobehavioral responses to lysergic acid diethylamide in healthy subjects: a randomized controlled study

Neuropsychopharmacology June 18, 2026 Abigail E. Calder, Vincent J Diehl, Morten P. Lietz et al.

Preclinical studies suggest that lysergic acid diethylamide (LSD) may induce lasting changes in brain function and learning ability, but evidence in humans is uncertain. Motor learning, in particular, has clinical relevance but has not been investigated in human studies of psychedelics. Forty-five healthy subjects (24 women) participated in this randomized crossover trial comparing 100 µg LSD...

DOI: 10.1038/s41386-026-02454-7 Full text Lysergic acid diethylamide Transcranial magnetic stimulation Electroencephalography Crossover study +11

Characterizing non-hallucinogenic psychedelics beyond the head twitch response: phenotypic fingerprinting of lisuride and LSD

Translational Psychiatry June 13, 2026 Jillian L. King, Devin P. Effinger, Cameron Basquez-Pfeifer et al.

The head-twitch response (HTR) is widely used as a preclinical assay for the hallucinogenic potential of compounds, with its utility based on 5HT 2A R activation. Here, we examine how the polypharmacological agonists lisuride and lysergic acid diethylamide (LSD) influence behavioral and physiological outcomes in mice to test whether the HTR reliably reflects overall psychoactivity. Lisuride...

DOI: 10.1038/s41398-026-04174-4 Full text Lisuride Phenotype Schizophrenia object-oriented programming Head geology +1

MM120 (lysergide D-tartrate) Receptor Binding and Evaluation in the Rat Following 13-weeks of Administration

European Psychiatry June 1, 2026 J. Tripp, G. Smagin

Introduction MM120 (lysergide D-tartrate, LSD, CAS 32426-57-6) is under development as a potential treatment for generalized anxiety disorder and major depressive disorder. MM120 may elicit profound lasting psychological changes through interaction with brain 5-HT1A, 1B, 2A, 2C, 6 and 7 receptors, among others, while the complete mechanism is not clear. Objectives The study was performed to...

DOI: 10.1192/j.eurpsy.2026.11606 Full text

MM120 (Lysergide) May Enhance Neuroplasticity by Post-Dose Upregulation of TrkB

European Psychiatry June 1, 2026 G. Smagin, J. Tripp

Introduction MM120 (lysergide D-tartrate, a formulation of LSD) is under development as a potential treatment for generalized anxiety and major depressive disorders. How psychedelic drugs interact at the TrkB receptor, a key target of neuroplasticity, is not reported. Objectives The study evaluated binding and functional activity of known serotonergic psychedelic compounds and SRI fluoxetine at...

DOI: 10.1192/j.eurpsy.2026.11607 Full text

Synthetic Drugs and Behavioural Addictions: LSD, MDMA and Digital Toxicity

June 1, 2026 Sharda More-Pol

The emergence of contemporary psychological stressors, synthetic psychoactive substance abuse, and non-substance behavioral dependency networks presents critical investigative challenges within public healthcare and classical toxicology (Agadatantra), traditionally analyzed through the concepts of Madya (intoxicants), Mada (intoxication), and severe cognitive perversion (Prajñāparādha). This...

DOI: 10.63247/ayurveda360.cfa.agadatantra.c011 Lysergic acid diethylamide MDMA Cognition Parallels +5

Who Keeps Using Lysergic Acid Diethylamide? Correlates of Past-Year Use in People Who Initiated Use at least Five Years Ago.

Psychedelic Medicine June 1, 2026 Brian S. Barnett, Akhil Anand, Jeremy Weleff et al.

Little is known about the correlates of repeated non-medical lysergic acid diethylamide (LSD) use. Therefore, we aimed to determine the prevalence and correlates of past-year LSD use among people aged 18 years and older in the United States who first used LSD at least 5 years ago. Using data from the 2015-2019 National Survey on Drug Use and Health, we examined the estimated weighted prevalence...

DOI: 10.1177/28314425251367321 Full text LSD Drug use Hallucinogen Psychedelics

Integrating the Mystical Experience Questionnaire Into a Broader Psychometric Framework: English Validation of the Psychedelic Experience Scale and Comparison of Psilocybin and LSD Sessions Across Two Controlled Settings.

International Journal of Methods in Psychiatric Research June 1, 2026 Kurt Stocker, Matthias Hartmann, Frederick S. Barrett et al.

For English, the validated part of Psychedelic Experience Scale (PES48) is a four-factor structure called the Mystical Experience Questionnaire (MEQ30). The other validated part of the PES48 consists of four more factors: two more mystical factors (paradoxicality and connectedness, which together with the MEQ30 form the MEQ40), and two more non-mystical factors (visual experience and...

DOI: 10.1002/mpr.70073 Full text Mystical experience Psychedelic experience Psychometrics Setting